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Effectiveness of Laboratory Animal Use
Combined, this represents an enormous commitment of animal, scientific, personnel, and financial resources, ostensibly dedicated primarily to the ad vancement of human health. But how effective has all this research been?
Advocates of such research have regularly claimed it is essential for pre venting, curing, or alleviating human diseases ( e.g., Brom, 2002; Festing, 2004) ; and further, that the greatest achievements of medicine have only occurred through the use of animals ( e.g., Pawlik, 1998) . However, those who champion such claims frequently have careers dependent on such research. Further more, counter-narratives by others contest the contributions or necessity of such research for the advancement of medical progress ( e.g., Greek and Greek, 2002 ) . To support their argument, advocates on either side regularly cite cases in which animal and human outcomes are similar or different. However, only small numbers of experiments are normally included in such reviews, and their selection may be subject to bias. These are known as narrative reviews.
To provide more definitive conclusions, systematic reviews of the human clinical or toxicological utility of large numbers of animal experiments are necessary. A systematic review is "a review of a clearly formulated question that uses systematic and explicit methods to identify, select, and critically ap praise relevant research and to collect and analyze data from the studies that are included in the review. Statistical methods (meta-analysis) may or may not be used to analyze and summarize the results of the included studies" (Moher et al., 2009 ) . In recent years, systematic reviews have become widely utilized to investigate a broad range of clinical and other research questions. Their aims are to retrieve as much high-quality evidence as possible, relevant to the research question, and to minimize bias during the selection, analysis, and reporting of results. Any conclusions reached should, accordingl y, be as close as possible to biological, physical, chemical, or other truths.
A large number of systematic reviews of animal experiments within various research fields have examined their utility for advancing human healthcare, and the results have not been good. Of 20 published systematic reviews exam ining human-clinical utility located during a comprehensive literature search, animal models demonstrated significant potential to contribute toward clini cal interventions in only two cases, one of which was contentious. Included were experiments approved by ethics committees on the basis of claims that medical advances were likely to result; highly-cited experiments published in leading journals; and chimpanzee experiments, utilizing the species most generally predictive of human outcomes. Seven additional reviews failed to demonstrate utility in reliably predicting human toxicological outcomes, including those associated with the greatest public health concerns, such as carcinogenicity and teratogenicity. Results in animal models were frequently equivocal or inconsistent with human outcomes (Knight, 2011 ) . Since then, numerous additional reviews have yielded similar results. Baker et al. (2014) , for example, examined human neurological disease, which has been exten sively studied in animal models, resulting in relatively few human treatments ( Cheeran et al., 2009; Vesterinen et al., 2010 ) . Similarly, despite reports of the efficacy of more than 1,000 treatments in animal models of multiple sclerosis (Ms), very few treatments have progressed to the marketplace (Vesterinen et al, 2010 ) . This usually indicates failures of efficacy or safety concerns in hu mans. And, despite the widespread use of animal models within stroke re search, virtually no interventions described as effective in animal models have proven similarly effective in human patients (Cheeran et al., 2009) . There are many other examples.
Several studies have sought to determine the maximal human clinical util ity that may be achieved by animal models, by examining chimpanzee ex periments, given that chimpanzees are our closest relatives (Knight, 2007) ; by examining experiments approved by ethics committees on the basis of explicit claims of likely human healthcare benefits (Lindi, Volkel and Kolar, 2005) ; or by examining highly-cited animal experiments published in leading scientific journals (Hackam and Redelmeier, 2006) . Hackam and Redelmeier, for example, located 76 animal experiments, each of which had been cited well over 500 times and published in one of the world's seven top scientific journals when ranked by journal impact factor. Hence, these experiments rep resented some of the most important and scientifically-interesting animal re search published at the time. In only 28 cases (36.8% ), animal results were later replicated in humans. Most animal research is neither highly cited nor published in world-leading journals, and successful translation to humans is far lower.
Limitations of Animal Models
A variety of factors appear responsible for the poor rates of translation of out comes from animal studies into human patients and consumers. These relate both to the animal models themselves and to the ways in which they are used. Fundamental biochemical differences between species may result in differ ences in absorption, distribution, metabolism, and elimination pathways or rates, which may alter toxico-or pharmaco-kinetics (i.e., bodily distribution). Toxico-and pharmaco-dynamics ( mechanisms of action and biological effects) may also be altered. Jointly these factors may contribute to differences in organ systems affected and in the nature and magnitude of those effects (Hartung, (Hartung, 2008; Knight, 2011) . Additional problems arise from the ways in which the animals are used. Many toxicity tests, for example, rely on maximum tolerated doses ( above which acute, toxicity-related effects preclude further dosing), and chronic dosing. These factors maximize sensitivity to toxins, with the result that false negative results rarely occur. However, these conditions can also overwhelm the physiological defenses that are effective at environmentally realistic doses, resulting in false positive outcomes. As a result, many compounds that would not normally be considered toxic are falsely indicated as such by animal tests; this substantially decreases the reliability and relevance of any positive result. Additionally, important human routes of exposure ( e.g., inhaled) may differ from those tested in animals, requiring extrapolation between routes of expo sure, as well as between species, introducing further uncertainty ( Gold, Slone and Ames, 1998; Hartung, 2008; Knight, 2011) .
Furthermore, animals used in laboratories commonly experience a sig nificant array of stressors. These include stresses incurred during handling, restraint, and other routine laboratory procedures; and, in particular, the stressful routes of dose administration common to toxicity tests. Orogastric gavaging, for example, involves the insertion of a tube into the esophagus for the forced administration of test compounds. Combined with environmental stressors ( e.g., due to limited space and environmental enrichment) and social stressors ( e.g., due to aggressive interactions between conspecifics ), these rep resent a significant body of stressors. These stressors can alter physiological, hormonal, and immune statuses and even cognitive capacities and behavioral repertoires, in ways that are not always predictable (Balcombe, Barnard and Sandusky, 2004; Balcom be, 2006; Baldwin and Bekoff, 2007 ) . The results may include alterations in the progression of diseases, in bodily responses to chemi cals and test pharmaceuticals, and in a range of other scientific outcomes, such as those dependent on accurate determination of physiological, behavioral, or cognitive characteristics ( for further discussion see Herrmann, 2019, Chapter 1; Jayne and See, 2019, Chapter 21).
Methodological Quality of Animal Studies
As if these were not problem enough, a sizeable body of recent studies and systematic reviews have confirmed the existence of significant methodological Knight, 2008b ) . Indeed, to date, no systematic reviews appear to have been published in which a ma jority of animal studies, assessed against appropriate objective criteria, were found to have been of good methodological quality. In particular, a variety of design features must be included within animal experiments to minimize the potential for bias. Hooijmans et al (2014) described 10 types of bias that have the potential to influence animal experimental results, which they grouped into selection bias, performance bias, detection bias, attrition bias, reporting bias, and other sources of bias. Many of these flaws are highly prevalent within animal studies. Kilkenny et al. ( 2009) conducted one of the largest and most comprehensive systematic surveys to date, assessing the experimental design, statistical analy sis, and reporting of published animal experiments. 271 papers were examined, which included 72 studies using mice, 86 using non-human primates, and 113 using rats. Most (99%; 269/271) of these papers were published between 2003 and 2005. They covered a wide variety of experimental fields, were published in a comprehensive range of journals, and were funded by leading grant agencies within the United Kingdom and the United States. However, only 59% of these studies clearly stated the h yp othesis or objective of the study and the number and characteristics of the animals used. Details, such as animal strain, sex, age, and weight, are all scientifically important and can potentially influence results (Alfaro, zoos; GV-Solas, 1985; Obrink and Rehbinder, 2000 ) . Nevertheless, in many cases these details were omitted.
Knowledge of planned treatment ( or lack thereof) is one of a number of fac tors that can unconsciously influence the assignment of animals to treatment groups, for example, when researchers sympathetically select animals they consider weaker, to be used as controls, rather than test animals. The intro duction of such confounding factors (in this case, variable animal fitness), can potentially bias results (in this case, selection bias has occurred). Accordingly, randomized selection of animals for treatment groups is mandated, to ensure that outcome differences are most likely due to treatment effects (Festing and Altman, 2002; . Haphazard selection does not give sufficient certainty that results are truly random, so a systematic approach is necessary, such as the use of a random number generator (Kilkenny et al., 2009) . Never theless, despite its well-acknowledged importance, randomized allocation of animals to test groups was reported in only 12% of these studies.
Another crucial feature of good experimental design concerns the assess ment of outcomes. Where qualitative assessments occur, which involve assessor judgements, it is similarly crucial that assessors do not know ( are blinded to) the treatment ( or lack thereof) of the animals assessed, lest such knowledge Kathrin Herrmann and Kimberley Jayne -978-90-04-39119-2 Downloaded from Brill.com11 /11 /2019 09:57:0BPM via free access subtly affect their judgement (Festing and Altman, 2002 ) . Because, as Co chrane (1972) noted, "When humans have to make observations there is always the possibility of bias;' even unintentional bias. Nevertheless, only 14°/o (5/35) of all papers in the survey by Kilkenny et al. ( 2009) that reported qualitative assessment of outcomes, also reported the use of blinding. Many factors can affect experimental outcomes, so the incorporation of measures to minimize sources of bias is crucial to ensuring the reliability of re search results. And yet, 87°/o of papers, examined by Kilkenny and colleagues, failed to report randomization during animal selection; and 86% failed to report blinded assessment of outcomes. Additionall y, only 70% of the publi cations that used statistical methods described their methods and presented the results with a measure of error or variability. More recently, similar results were found in an even larger study. Vogt et al. ( 2016) determined the prevalence of seven basic measures against bias (i.e., allocation concealment, blinding, randomization, sample size calculation, inclusion/exclusion criteria, primary outcome variable, and statistical analysis plan), within 1,277 experimental ap plications approved by Swiss authorities in 2008, 2010 , and 2012 and within 50 subsequent publications. Measures against bias were reported at very low rates, both in experimental applications ( 2%-19%) and in subsequent publica tions ( 0%-34% ).
The importance of randomization and blinding when comparing two or more experimental groups has been highlighted by reviews of animal research in the field of emergency medicine, which have found that estimates of treat ment efficacy were significantly reduced in studies that incorporated these mechanisms to reduce risks of bias (Bebarta, Luyten and Heard, 2003; Macleod et al., 2008) . Similar results have been found in numerous other studies. In fact, studies incorporating the fewest measures to minimize sources of bias tended to report the greatest effect sizes ( Crossley et al., 2008; Hirst et al., 2014; Macleod et al., 2005; Rooke et al., 2011; Vesterinen et al., 2010 ) . The widespread failure to utilize mechanisms, such as randomization and blinding, appears to result in false expectations of treatment efficacy and reported outcomes in animals often fail to translate into humans. Similar results were reported following a literature review by Holman, Head, Lanfear and Jennions (2015) . They found that blind protocols are uncommon in the life sciences, and that non-blind studies tend to report more significant outcomes and higher effect sizes. They noted that: "Observer bias and other 'experimenter effects' occur when researchers' expectations influence study outcome. These biases are strongest when researchers expect a particular result, are measuring subjective variables, and have an incentive to produce data that confirm predictions. To minimize bias, it is good practice to work 'blind,' meaning that experimenters Kathrin Herrmann and Kimberley Jayne -978-90-04-39119-2 Downloaded from Brill.com11 /11 /2019 09:57:0BPM via free access are unaware of the identity or treatment group of their subjects while conduct ing research" (p. 1). Another common problem observed by Kilkenny et al. (2009) concerned the transparency of reporting, and the robustness of statistical analysis. Al most 60% of surveyed publications were deficient in these areas. Most stud ies failed to provide sample sizes or adequate justifications of them. And yet, studies that use too many animals waste animal lives. Conversely, the results of underpowered studies (with insufficient numbers of experimental sub jects) cannot be extrapolated to wider populations with sufficient certainty. Accordingly, power analyses or other simple calculations are widely used in human clinical trials to ensure enough subjects (but not more) are pres ent to detect biologically important effects. Indisputably, the same principles should apply to animal studies (Dell, Holleran and Ramakrishnan, 2002; Fest ing and Altman, 2002) .
Unfortunately, methodological flaws appear to be prevalent even within an imal research conducted at highly-ranked universities and published in lead ing journals. After studying 814 randomly-selected studies reporting primary research, 2,671 publications reporting drug efficacy in eight disease models, and 4,859 publications from five UK institutions ranked highest across six units of assessment in biomedical sciences, in the 2008 National Research Assess ment Exercise, Macleod et al. ( 2015) reported that severe deficiencies of experi mental design remain the norm. These deficiencies were prevalent in research conducted at leading UK research universities, in research funded by leading UK funding organizations, and in research reported in high-impact journals.
Evidence-based Research within Human Clinical Trials
The importance of sound experimental design, and, particularly, the neces sity of incorporating factors designed to minimize bias risks have long been recognized within the field of human research. The Consolidated Standards of Reporting Trials (CONSORT) Statement for randomized controlled human clinical trials was one of the first guidelines developed to ensure the quality of human-based research. It provides an evidence-based, minimum set of rec ommendations, including a checklist of 25 recommended items that should be included when reporting randomized human trials (Moher, Schulz and Altman, 2001; Schulz, Altman and Moher, 2010 ) . Since then, more than go guidelines have been developed for reporting different types of health research (see Altman et al., 2008; Simera et al., 2010;  www.equator-network.org). An increasing number ofleading journals have, subsequently, requested that their authors comply with the CONSORT guidelines (Altman, 200s; Hopewell et al., 2008 items, designed to provide mini mum information on items, such as the number and specific characteristics of animals used (including species, strain, sex, and genetic background); hous ing and husbandry conditions; and the experimental, statistical, and analytical methods used. The latter points included measures to reduce bias, such as the random allocation of animals to experimental groups, blinded assessment of outcome measures, statistical justifications of sample sizes, reporting of ani mals excluded from analyses, exclusion criteria, and any investigator conflicts of interest. The intention was that these items should be included within all scientific publications reporting animal research, thereby allowing critical as sessment of methods used and results obtained. Hooijmans et al. ( 2010) similarly proposed a Gold Standard Publication Check list ( GSPC ), which includes 74 items designed to improve the quality of animal studies and to fully integrate 3Rs "(replacement, reduction and refinement)" methods and facilitate their incorporation within systematic reviews and meta analyses. In 2014, Hooijmans and colleagues also proposed a Risk of Bias (RoB) tool to assess methodological quality and risk of bias within animal studies. The tool is based on the similar Cochrane RoB tool (Higgins et al., 2011) , which was adjusted for particular aspects of bias that play a role in animal studies.
Other authors have proposed similar guidelines and checklists for the con duct and reporting of animal research. Such guidelines provide indisputable benefits in ensuring the reporting of methodological quality, reliability of results, and incorporation of the 3R principles of animal research. The ARRIVE guidelines of Kilkenny et al. ( 2010) have been published or endorsed by more than 1,000 research journals, includ ing those published by the Nature Publishing Group, PLoS, and BioMed Cen tral (Reichlin, Vogt and Wiirbel, 2016 (Baker et al., 2014) . And yet, despite such widespread endorsement, a number of studies have demonstrated that com pliance with such guidelines remains poor. Noting that, "Despite reports of over 1,000 treatments effective in animal models of multiple sclerosis (Ms), very few treatments have so far made it to the marketplace following initial development in disease-related animal models (Vesterinen et al., 2010) ,' ' Baker et al. (2014) investigated the general adequacy of reporting within animal studies of MS. They uncovered signifi cant inadequacies within the reporting of experimental design, including the selection of appropriate statistical analyses and the application of key points in the ARRIVE guidelines. They observed that the ARRIVE guidelines are not being implemented by authors, reviewers, and journal editors (Baker and Amor, 2012; Landis et al., 2012; Schwarz, Iglhaut and Becker, 2012 ) .
Despite their very widespread publication and endorsement, lack of aware ness of such guidelines appears to remain a major problem. After survey ing all registered in vivo researchers in Switzerland recently, Reichlin et al. (2016) reported that among 302 self-selected participants, 56.3°/o did not know of the ARRIVE Guidelines. A total of 1,891 researchers were surveyed, but only 302 (16%) returned fully-completed questionnaires and, hence, were not excluded. Even among those whose latest paper was published in a journal that had endorsed the ARRIVE guidelines, 51% had never heard of them. The failure of biomedical journals to insist on compliance with quality control standards is partly to blame. After surveying 236 biomedical journals' policies on animal research, Osborne et al. ( 2009) found no mention of animal use, within author guidelines or elsewhere, in 35°/o of journals studied. In 18% of the journals, animals were mentioned, but no perceptible guidelines were provided; and most of the remaining journals scored poorly, with 37°/o scor ing three or fewer points out of 12 equally weighted items within their quality checklist. Martins and Franco (2015) examined 170 journals that publish stud ies on animal models of three human diseases, namely Amyotrophic Lateral Sclerosis (AL S, also known as Motor Neuron Disease); Type-1 Diabetes; and Tuberculosis. Their results were broadly similar to the results of a survey by Osborne et al.'s. (2009) , when assessing studies using their EXEMPLAR scale. They noted that, "little progress found regarding in-house policies on the ethi cal treatment of animals is worrisome" (p. 325).
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Improving Stud y Quality A range of measures are strongly warranted to increase the implementation of the 3R principles, the methodological quality of animal research, and the reli ability of results and to overcome some of the barriers that currently prevent reliable extrapolation to human outcomes. Compliance with each of the 3Rs and the ARRIVE guidelines and other best practice standards, during the design, conduct, and reporting of experiments, must become mandatory. Such standards should cover animal sourcing, hous ing, environmental enrichment, socialization opportunities, appropriate use of anesthetics and analgesics, handling, non-invasive endpoints, and a range of measures designed to minimize sources of bias and to ensure methodologi cal quality. Compliance with such standards should be a necessary condition for securing research funding and ethical approval; licensing of researchers, facilities, and experimental protocols; and publication of subsequent results. Compliance would also facilitate subsequent systematic reviews.
Where journal space constraints limit the description of methodological details, these should be included in supplementary online databases, which are now widely available (Kilkenny et al., 2009 ). This would also facilitate the transfer of alternative technologies, such as the development of new alterna tive methods, between institutions ( Gruber and Hartung, 2004 ) .
To enable animal researchers and technicians to meet the necessary stan dards, training and continuing professional development in 3R methodologies and the design, conduct, and reporting of animal research should be compul sory. The existing lack of focus on replacement methods ( in favor of refinement methods) must be addressed.
The adoption of measures, such as these, would increase the reliability of re search results and would facilitate their use within systematic reviews. Prior to designing any new animal study, researchers should conduct a systematic review to collate, appraise, and synthesize all existing, good-quality evidence relating to their research questions. Such systematic reviews should be similarly required by grant agencies, ethical review committees, other animal-experiment licens ing bodies, and journals. Systematic reviews are studies in and of themselves. In recognition of their intrinsic value, and their necessity for informing further re search, they should also be readily funded by grant agencies.
To ensure that all such evidence is publicly available, greater efforts must also be made by researchers and editors to publish negative results. Studies that fail to show a treatment effect are often considered less interesting and are, consequently, less likely to be published. The subsequent exclusion of such results from systematic reviews leads to over-estimations of treatment efficacy and partly explains the widespread failures in humans of treatments appar ently efficacious in animals.
Within the field of human studies, clinical trial registers allow researchers to learn about existing and prior clinical trials, including those with negative outcomes, before results are formally published. A similar international ini tiative to register animal studies and their results is warranted (Hooijmans et al., 2014) .
Many of these measures will require cooperation and coordination between researchers, regulators, licensing bodies, ethical review committees, fund ing bodies, journals, and authors. And of course, the necessary willingness, among all parties, to change. If these measures were to be successfully imple mented throughout the broad field of animal research, then we may be able to predict treatment effects accurately within the animal species under study. However, interspecies differences will remain in absorption, distribution, me tabolism, and elimination pathw ay s or rates, resulting in differing toxico-or pharmaco-kinetics and dynamics and, subsequently, differences in the organ systems affected and in the nature and magnitude of these effects. Such fac tors, which reflect the intrinsic complexity of living organisms, will continue to pose barriers to extrapolation to humans that will remain insurmountable, in many cases. cause significant stress, fe ar, and possibly distress in laboratory animals. These stressors may be associated with the capture of wild-sourced species, such as primates, to supply laboratories or breeding centers; with transportation, which may be prolonged for some animals; with laboratory housing and en vironments; and with both routine and invasive laboratory procedures ( see Knight, 2011 ). An invasive procedure is an intervention that interferes with bodi ly integrity through puncture, incision, or insertion of an instrument or foreign material, as in surgical and some experimental procedures (Knight, 2011) .
A large minority of all procedures are markedly invasive. These include pro cedures resulting in death ( whether or not the animals are conscious); surgical procedures ( excluding very minor operative procedures); major physiological challenges; and the production of genetically-modified animals. Few regions report procedural invasiveness, but Canada does. From 1996-2008 inclusively, the proportion of markedly invasive procedures reported in Canada ranged between approximately 29%-44°/o (Canadian Council on Animal Care, 2009). These procedures were defined by the Canadian Council on Animal Care ( 2009) as resulting in moderate to severe stress or discomfort ( Category D ); or in severe pain near, at, or above the pain tolerance threshold of unanesthetized conscious animals (Category E) compared to procedures resulting in little or no discomfort or stress (Category B) or minor stress or pain of short duration ( Category C).
A sizeable majority of all procedures utilize no anesthetics of any kind. Few regions report anesthetic usage, but Britain does. During two recent decades (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) , the proportion of procedures conducted in the UK without anes thesia fluctuated between approximately 59%-69% (Home Office, 2010 ). For example, in 2009, at the end of this period, 66.7°/o of cases did not utilize any form of anesthesia. General anesthesia was provided throughout or at the end of terminal procedures in 9.5% of cases. In 17.1% of cases, general anesthesia with recovery was provided, and in 6.7°/o of cases, local anesthesia (Home Office, 2010 ).
To assess animal impacts further, it is helpful to know the frequency of anal gesic (pain-killer) use, and the level of correlation between markedly invasive procedures and anesthetic or analgesic use ( See Herrmann and Flecknell ( 2018) for a review of original animal research proposals). Painful or invasive proce dures warrant anesthesia and/or analgesia. Animal welfare is adversely affect ed when animals undergoing such procedures are denied these; or conversely, when they are provided without sufficient need ( due to their potential side effects), although this is rare in practice. It would also be helpful to study the prevalence of environmental enrichment and socialization opportunities. Un fortunatel y, such information remains largely unreported.
Conclusions
Animal research is a mechanism by which we seek to increase our understand ing of the biological world. The major useful applications of this knowledge lie in the development of new therapies for combatting human diseases and in predicting the human toxicity of chemicals used for a wide range of purposes. As we have seen, however, the actual efficacy of animal research for these pur poses is very low. This is due to a range of causes, some of which are, at least theoretically, amenable to change and some of which are not.
When formulating social policy pertaining to animal research, the social benefits realized are only part of the equation. The other major part that must be considered concerns the resources consumed by this research. The very substantial financial and scientific resources consumed by animal research are consequently unavailable to other fields, some of which, such as preventa tive healthcare or human clinical research, may well be expected to produce greater gains for public health. And as we have seen, the impacts on animals are also severe. 127 million living non-human vertebrates were used worldwide in 2005, the most recent year for which an evidence-based global estimate was available. Based on figures from countries, such as Canada and the UK, where these are published, a large minority of all procedures are markedly invasive; and a sizeable majority utilize ( or at least report) no anesthetics of any kind.
The core ethical principle underpinning modern animal experimentation regulation and policy is that the likely benefits of such research must out weigh its expected costs. This utilitarian harm-benefit analysis underpins all fundamental regulation governing animal experimentation. For example, Eu ropean Directive 2010/63/EU on the protection of animals used for scientific purposes, which directs such animal use in all EU Member States, asserts that it is "essential, both on moral and scientific grounds, to ensure that each use of an animal is carefully evaluated as to the scientific or educational validity, usefulness, and relevance of the expected result of that use. The likely harm to the animal should be balanced against the expected benefits of the project" (European Parliament, 2010, p. 37 ) .
When considering harms and benefits overall, one cannot reasonably con clude that the benefits accrued for human patients or consumers, or those mo tivated by scientific curiosity or profit, exceed the harms incurred by animals subjected to scientific procedures. On the contrary, evidence indicates that ac tual human benefit is rarely, if ever, sufficient to justify such harms. And those harms are not limited to the many millions of animals used. Others poten tially affected include patients and consumers. The social and ethical implica tions are profound, when consumers suffer serious toxic reactions to products assessed as safe in animal studies, or if patients with serious conditions are denied effective clinical interventions, partly because potentially more effica cious research fields are under-resourced (Knight, 2011) .
A paradigm change in scientific animal use is clearly warranted. Instead of uncritically assuming the benefits of animal research, we must subject it to much more rigorous and critical evaluation. Where animal research continues to persist, a broad range of measures must be implemented to improve sub stantially its methodological quality and compliance with the 3Rs and to maxi mize the reliability of subsequent results (Knight, 2011) . When such research fails to meet the harm-benefit standards expected by society, which under pin legislative instruments, such as Directive 2010/63/EU, then such research should cease; and the resources consumed by it directed into more promising and justifiable fields of research and healthcare.
